GHK-Cu Topical: How Copper Peptide Serums and Creams Actually Work

A tripeptide small enough to slip through skin, a metal ion woven into the chemistry of nearly every tissue in the body, and decades of research converging on a single question: can a copper-binding molecule applied to the surface of the skin actually reach the cells that need it, and when it does, does it change anything that matters? GHK-Cu, the copper complex of the tripeptide glycine-histidine-lysine, has been circulating in anti-aging skincare since the 1990s, but the science beneath the marketing has only recently caught up to the enthusiasm. Understanding how GHK-Cu topical formulations work, where the evidence is strongest, and where it remains thin, requires starting not at the cosmetics counter but in the plasma of healthy young adults.

GHK was first isolated from human plasma by Loren Pickart in 1973, identified as a fragment that appeared to stimulate liver tissue repair [1]. The observation was initially puzzling: this tiny three-amino-acid chain, bound to a copper ion, seemed to orchestrate tissue remodeling out of all proportion to its size. Subsequent work revealed that GHK-Cu plasma concentrations decline sharply with age, from roughly 200 nanograms per milliliter at age 20 to under 80 nanograms per milliliter after age 60 [2]. That gradient has driven two decades of research into whether replenishing GHK-Cu, either systemically through injection or locally through topical application, can restore some of the regenerative signaling associated with younger biology.

The Biology Behind the Peptide: What GHK-Cu Actually Does

To appreciate why a three-amino-acid peptide attracts serious scientific attention, it helps to understand the range of processes it appears to regulate. GHK-Cu is not a simple growth factor that switches on a single receptor. It operates more like a conductor, coordinating expression across a surprisingly wide network of genes. A 2012 analysis using the Broad Institute's Connectivity Map found that GHK-Cu modulated the expression of 31.2 percent of all human genes with high confidence, with particularly strong effects on pathways governing collagen synthesis, anti-inflammatory signaling, antioxidant defense, and DNA repair [3].

The copper component is not incidental. Copper is a cofactor for lysyl oxidase, the enzyme that crosslinks collagen and elastin fibers to give skin its tensile strength and elasticity. It is also essential for cytochrome c oxidase, the terminal enzyme of the mitochondrial electron transport chain. When GHK binds copper and delivers it to cells, it is not simply shuttling a mineral; it is supplying the raw material for structural and energetic machinery that degrades with age. Think of GHK as a specialized courier service, one whose job is specifically to move a cargo that most delivery systems cannot carry reliably.

At the cellular level, GHK-Cu promotes fibroblast proliferation and migration, the two behaviors most critical for wound healing and dermal remodeling [4]. Fibroblasts are the cells in the dermis responsible for synthesizing collagen, elastin, and the glycosaminoglycans that give skin its hydration and volume. With age, fibroblast activity declines and their secretory profile shifts: they produce less type I and type III collagen, more matrix metalloproteinases (enzymes that degrade the extracellular matrix), and fewer of the anti-inflammatory cytokines that keep chronic low-grade inflammation in check. GHK-Cu appears to reverse several of these age-related changes simultaneously, upregulating collagen synthesis while downregulating matrix metalloproteinase activity, a combination that in younger tissue represents normal homeostasis and in older tissue looks like partial restoration [5].

Beyond structural proteins, GHK-Cu exerts anti-inflammatory effects that are relevant not just to skin aging but to the broader concept of inflammaging, the chronic low-grade systemic inflammation that underlies most age-related disease. It suppresses the activity of nuclear factor kappa-B (NF-kB), a transcription factor that functions as a master switch for inflammatory gene expression, and increases the activity of antioxidant enzymes including superoxide dismutase and catalase [2]. In this light, topical GHK-Cu is not simply a cosmetic intervention. At the tissue level, it is modulating the same inflammatory and oxidative stress pathways that longevity researchers target systemically.

The Penetration Problem: Getting Copper Peptides Through the Skin Barrier

The skin's outermost layer, the stratum corneum, is one of the most effective barriers in human biology. Its architecture, often likened to bricks (corneocytes) held together by mortar (lipid lamellae), is specifically evolved to exclude large hydrophilic molecules. This presents an immediate challenge for any topically applied peptide: to do anything useful, GHK-Cu must cross this barrier and reach the viable epidermis and dermis where fibroblasts, keratinocytes, and hair follicle cells reside.

The molecular weight of the GHK tripeptide alone is approximately 340 daltons, well within the conventional 500-dalton rule of thumb for skin penetration of small molecules. When complexed with copper, the total molecular weight remains low enough that passive diffusion through the stratum corneum is theoretically plausible [5]. Experimental studies using pig skin models and human skin explants have confirmed measurable transdermal penetration under appropriate formulation conditions, though the fraction that ultimately reaches the dermis varies considerably depending on vehicle chemistry, pH, copper concentration, and the integrity of the skin barrier [5].

Formulation matters enormously. GHK-Cu is hydrophilic, which means oil-based vehicles will generally impede its penetration rather than enhance it. Water-based serums with penetration enhancers such as hyaluronic acid, niacinamide, or certain glycols tend to outperform heavy creams in delivering the peptide to viable skin layers. pH also plays a role: the copper complex is most stable and most bioavailable in a slightly acidic environment, consistent with normal skin surface pH of around 4.5 to 5.5. Formulators who optimize for stability and penetration simultaneously produce products that behave very differently in clinical testing from those that simply include GHK-Cu as a label ingredient without these considerations.

The follicular route deserves separate attention, particularly for hair applications. Hair follicles penetrate deeply into the dermis and provide a direct channel that bypasses the stratum corneum almost entirely. For applications targeting hair growth or scalp health, this pathway may be more relevant than transdermal diffusion, and it partly explains why the evidence for GHK-Cu in hair loss is mechanistically plausible even when general skin penetration data remains mixed.

Clinical Evidence for Skin: Wrinkles, Collagen, and Wound Healing

The strongest evidence for topical GHK-Cu in skin comes from studies examining collagen synthesis, skin density, and the appearance of photodamage. A double-blind, split-face study published in the American Journal of Clinical Dermatology compared a GHK-Cu cream to a vehicle control over 12 weeks in women with mild to moderate facial aging. Treated sides showed statistically significant improvements in skin laxity, roughness, and fine line depth assessed by standardized photography and profilometry, alongside histological evidence of increased dermal collagen density confirmed by biopsy [6]. The magnitude of effect was modest but measurable: collagen density increased by approximately 14 percent in the treated group versus no significant change in controls.

A separate controlled trial examined GHK-Cu peptide cream against a retinol formulation and a vehicle control, measuring skin thickness by ultrasound and surface parameters by optical profilometry over 12 weeks [6]. Both active groups outperformed vehicle, and the GHK-Cu and retinol groups produced comparable improvements in most parameters. This is a clinically meaningful benchmark: retinoids are among the most extensively validated topical anti-aging compounds in dermatology, and a copper peptide matching their performance in a head-to-head comparison is a finding worth taking seriously.

Wound healing represents the area with the longest and most consistent evidence base for GHK-Cu. Multiple animal studies and several human wound models have demonstrated accelerated re-epithelialization, reduced inflammation, and increased angiogenesis (the formation of new blood vessels to support healing tissue) with GHK-Cu application [4]. These effects are mechanistically coherent with everything known about how the peptide works at the cellular level: fibroblast recruitment, collagen synthesis, and anti-inflammatory signaling are exactly what a healing wound requires. The wound healing data also provides indirect support for the skin aging applications, since the biological processes involved in repairing acute damage overlap substantially with those involved in countering chronic photo-damage and intrinsic aging.

A copper peptide matching retinol's performance in a head-to-head comparison of skin density and fine-line reduction is not a cosmetic curiosity. It is a finding that repositions GHK-Cu in the evidence hierarchy for topical anti-aging interventions.

Photoprotective and antioxidant effects have also been documented in cell culture and animal models. GHK-Cu reduces ultraviolet-induced DNA damage markers and increases the expression of DNA repair genes including those in the base excision repair pathway [2]. Whether these effects are clinically meaningful when the peptide is applied topically to intact human skin, where it must first penetrate to reach nucleated cells, remains an open question. The mechanistic evidence is compelling; the human clinical data for photoprotection specifically is thinner.

Hair Loss and Scalp Health: The Evidence for GHK-Cu in Androgenetic Alopecia

Androgenetic alopecia, the pattern hair loss that affects roughly 50 percent of men by age 50 and up to 40 percent of women by age 70, is driven primarily by dihydrotestosterone (DHT) acting on genetically susceptible follicles to progressively miniaturize them [7]. The standard pharmacological treatments, minoxidil and finasteride, address only part of the biology: minoxidil extends the anagen (growth) phase while finasteride reduces DHT production. Neither directly addresses the inflammatory component of follicle miniaturization, which is increasingly recognized as a significant contributor to the process.

GHK-Cu's potential role in hair loss sits at the intersection of its pro-angiogenic, anti-inflammatory, and stem cell activating properties. Hair follicle cycling depends critically on blood supply: the dermal papilla, the cluster of specialized cells at the follicle base that directs hair growth, is one of the most vascularized structures in the skin. GHK-Cu stimulates vascular endothelial growth factor (VEGF) and increases the density of capillaries around follicles in animal models, an effect analogous to, though mechanistically distinct from, minoxidil's vasodilatory action [5].

In cell culture models, GHK-Cu has been shown to activate follicle stem cells and promote the transition from telogen (resting phase) to anagen (growth phase), which is precisely the effect both patients and clinicians are looking for [5]. A study using human hair follicle organ cultures found that GHK-Cu extended anagen duration and reduced premature catagen entry (the regression phase that ends each growth cycle) by mechanisms involving Wnt/beta-catenin signaling, a pathway critical for follicle development and regeneration [2].

Human clinical data for topical GHK-Cu as a standalone treatment for androgenetic alopecia remains limited compared to the mechanistic evidence. The most compelling human study to date examined a topical GHK-Cu solution applied to the scalp of men with grade II-III androgenetic alopecia over 6 months. Participants showed a statistically significant increase in hair density compared to vehicle control, with results approaching but not quite matching those seen with standard minoxidil in comparable trial designs [5]. This positions GHK-Cu as a promising adjunct or alternative for patients who cannot tolerate minoxidil's side effects, rather than a replacement for established therapies.

For patients concerned about hair loss alongside scalp aging, the combination of GHK-Cu with evidence-based scalp treatments represents an area of growing clinical interest. Topical Rapamycin+ for Hair works through a completely different mechanism, mTOR pathway modulation, suggesting that combination approaches targeting multiple aspects of follicle aging simultaneously may produce additive benefits, though this remains to be tested in prospective human trials.

Injectable Versus Topical GHK-Cu: A Mechanistic Comparison

The question of whether topical or injectable GHK-Cu produces superior biological effects is not as simple as bioavailability arithmetic might suggest. The two routes of administration distribute the peptide to fundamentally different compartments and at different concentrations, making direct comparison difficult and the "better" choice entirely context-dependent.

Injectable GHK-Cu, administered subcutaneously or intravenously, achieves systemic distribution. Peak plasma concentrations following injection exceed anything achievable by topical application by several orders of magnitude, and the peptide reaches tissues throughout the body including the liver, lung, and central nervous system. This systemic distribution may be relevant for GHK-Cu's broader effects on inflammation, DNA repair, and mitochondrial function, which have been documented in organs well beyond the skin [3]. For applications targeting systemic aging biology rather than skin-specific endpoints, the injectable route has a mechanistic rationale that topical application cannot match.

However, systemic distribution comes with a practical limitation: the peptide is rapidly cleared from plasma, with a half-life measured in minutes to hours. Frequent dosing is required to maintain any sustained elevation of circulating GHK-Cu, and the dose-response relationship for systemic effects in humans remains poorly characterized. Unlike established peptide therapies where pharmacokinetic data informs dosing protocols, GHK-Cu injection protocols in current clinical use are largely empirical.

Topical application, by contrast, concentrates the peptide precisely where most users want it: the skin and scalp. For local endpoints, this targeted delivery may actually outperform systemic administration by achieving higher local tissue concentrations than would be possible from plasma distribution alone. A molecule absorbed into the dermis from above does not have to compete with systemic clearance before reaching dermal fibroblasts. In this sense, topical GHK-Cu is not an inferior version of injectable GHK-Cu. It is a different intervention with a different target distribution profile and correspondingly different optimal use cases.

Topical GHK-Cu is not an inferior version of injectable GHK-Cu. It is a different intervention: one that concentrates the peptide where most users actually want it, bypassing systemic clearance to achieve local tissue levels that injection cannot replicate.

Safety profiles also differ between routes. Topical GHK-Cu has an excellent tolerability record across decades of cosmetic use, with contact sensitization being the primary reported adverse effect and occurring at low rates [6]. Injectable GHK-Cu carries the standard risks associated with any subcutaneous or intravenous peptide administration: injection site reactions, infection risk, and the theoretical concern, not yet clinically documented, that supraphysiological systemic concentrations could have unintended effects on tissues beyond the skin. Long-term safety data for injectable GHK-Cu in humans is substantially thinner than for the topical formulations, which have a multi-decade record in cosmetic dermatology.

Comparing GHK-Cu to Other Topical Anti-Aging Interventions

Understanding where GHK-Cu sits relative to other established topical anti-aging interventions helps clinicians and patients make rational formulation choices. The landscape includes retinoids (vitamin A derivatives), vitamin C (ascorbic acid), niacinamide, growth factors, and more recently, topical rapamycin. Each operates through a distinct mechanism, and none of them renders the others obsolete.

Retinoids remain the most extensively studied topical anti-aging compounds in clinical dermatology, with randomized controlled trial evidence spanning more than three decades for tretinoin, the active prescription form. Tretinoin increases epidermal turnover, stimulates collagen synthesis through retinoic acid receptor activation, and reduces matrix metalloproteinase activity. The head-to-head data with GHK-Cu showing comparable efficacy in some parameters is notable, but retinoids have a far larger and more rigorous evidence base, and their limitations, photosensitivity, irritation, and teratogenicity, are also well characterized [6].

Vitamin C at high concentrations (10 to 20 percent L-ascorbic acid) provides well-documented photoprotective effects through free radical scavenging, and acts as an essential cofactor for prolyl and lysyl hydroxylase, the enzymes that stabilize the collagen triple helix. It is mechanistically complementary to GHK-Cu rather than redundant with it, which is why many clinically informed formulations include both. The practical challenge with vitamin C is stability: ascorbic acid oxidizes rapidly in aqueous solution, limiting shelf life and requiring careful packaging to preserve potency.

Topical Rapamycin for Skin represents a mechanistically distinct approach that targets the mTOR pathway, downregulating cellular senescence and restoring the youthful gene expression signature in aged keratinocytes. A randomized controlled trial demonstrated that rapamycin cream applied twice weekly for eight months reduced p16 expression (a marker of cellular senescence) and improved several clinical skin aging parameters in older adults [8]. This mechanism is largely orthogonal to GHK-Cu's collagen-stimulating and anti-inflammatory effects, suggesting genuine complementarity for patients interested in addressing multiple hallmarks of skin aging simultaneously.

Niacinamide (vitamin B3) reduces melanin transfer, strengthens the skin barrier, and has modest anti-inflammatory effects. It is one of the most broadly tolerated topical actives available. Its mechanism of action does not substantially overlap with GHK-Cu's, and it functions well as a co-ingredient in multi-active formulations.

The key distinction for evidence-based formulation decisions is that GHK-Cu occupies a relatively unique niche: it combines matrix-remodeling effects with anti-inflammatory and pro-healing properties in a single molecule, making it particularly well-suited to compromised or post-procedural skin where barrier integrity is reduced. This is also where its penetration advantages are greatest, since a disrupted barrier allows deeper delivery to the dermis.

Formulation Science: What Separates Effective Products from Label Claims

Not all GHK-Cu products are equivalent, and the gap between a well-formulated copper peptide serum and one that simply lists the ingredient on the label can be substantial. Several formulation variables determine whether a product will deliver meaningful concentrations of intact GHK-Cu to viable skin cells or simply coat the skin surface with a largely inactive preparation.

Concentration is the first variable. GHK-Cu is typically used at concentrations between 0.01 and 2 percent in topical formulations. Below roughly 0.1 percent, in vitro evidence suggests biological activity is minimal. The sweet spot in most experimental work has been in the 0.5 to 1 percent range, balancing efficacy against the risk of pro-oxidant effects that have been observed at very high copper concentrations, a concern with any metal ion [5]. Products that do not disclose concentration leave consumers unable to make evidence-informed comparisons.

pH is the second critical variable. GHK-Cu is a coordination complex, and its stability depends on maintaining an appropriate pH range. Formulations buffered to pH 4.5 to 5.5 best preserve the copper-peptide bond and align with normal skin surface pH, maximizing both stability during storage and bioavailability after application. Alkaline vehicles, particularly those above pH 7, risk premature dissociation of the copper from the peptide, rendering the complex inactive before it can penetrate.

The vehicle itself shapes penetration kinetics profoundly. Water-based serums with low molecular weight humectants typically deliver GHK-Cu more effectively to viable skin than heavy emollient creams, because the aqueous vehicle stays close to the hydrophilic peptide's thermodynamic comfort zone and the thin film left on skin after absorption is more conducive to transdermal flux. Some advanced formulations use encapsulation technologies, liposomes or polymeric nanoparticles, to protect the peptide from degradation and extend its contact time with the skin surface, though clinical data specifically demonstrating improved outcomes with encapsulated versus non-encapsulated GHK-Cu in human trials is still limited.

Interaction with other ingredients deserves careful attention. GHK-Cu should not be combined directly with strong chelating agents such as EDTA, which can strip the copper from the complex. It also shows reduced stability in the presence of high-concentration ascorbic acid in the same container, though the two can be used in separate steps in a skincare routine without issue. Formulators who understand these interactions design products accordingly; consumers who are combining products from different brands benefit from understanding the basic compatibility rules.

GHK-Cu and Systemic Aging: The Broader Longevity Context

Skin is not an island. The biological processes that govern dermal aging, chronic inflammation, oxidative stress, impaired DNA repair, mitochondrial dysfunction, and cellular senescence, are the same processes that drive aging in every other tissue. This is why GHK-Cu attracts attention that extends beyond dermatology into longevity medicine.

The gene expression data is striking. Bioinformatic analysis of GHK-Cu's transcriptional effects found extensive overlap with genes associated with extended lifespan in multiple model organisms. Specifically, GHK-Cu upregulated genes in pathways governing mitochondrial biogenesis, proteasomal function (the cellular machinery that clears damaged proteins), and sirtuin activity, while downregulating inflammatory and pro-senescent gene networks [3]. In Caenorhabditis elegans, the nematode that has become a workhorse for aging research, GHK tripeptide increased median lifespan by roughly 20 percent through mechanisms involving reduced oxidative stress and improved proteostasis [2].

Whether these observations translate meaningfully to human systemic aging biology remains genuinely uncertain. The C. elegans lifespan data, while reproducible, involves an organism with no skin in the evolutionary sense, and the doses used in animal studies do not map cleanly to human exposure levels from topical application. It would be intellectually dishonest to characterize a topical copper peptide serum as a longevity intervention in the same category as caloric restriction or mTOR inhibition based on current evidence.

What can be said with more confidence is that GHK-Cu's effects on local skin biology, reduced inflammation, increased collagen synthesis, improved DNA repair response, and enhanced cellular regeneration, represent meaningful interventions against the hallmarks of skin aging. And skin aging is not cosmetically trivial: the structural and barrier changes that accumulate over decades compromise the skin's role as an immune and protective organ, not just its aesthetic appearance. Treating skin aging with evidence-based topical interventions is a legitimate component of a comprehensive healthspan strategy, not a vanity project.

For those interested in addressing skin aging within a broader longevity framework, it is worth noting that systemic interventions targeting inflammation, metabolic health, and hormonal status also profoundly affect skin biology. Estrogen and testosterone both influence dermal collagen density, fibroblast activity, and skin hydration through well-characterized receptor-mediated mechanisms. Patients considering hormone optimization as part of a longevity program may find that the skin benefits of appropriately dosed hormonal support complement what topical GHK-Cu can achieve locally. Healthspan's Women's Hormone Health and Men's Hormone Health programs address this systemic dimension in the context of comprehensive longevity care.

Practical Application: How to Use GHK-Cu Topicals Effectively

Translating the mechanistic and clinical evidence into a practical application protocol requires attention to timing, layering order, and realistic expectations. The published evidence does not support miraculous transformations, but it does support measurable improvements in skin structure and appearance with consistent use of well-formulated products over 8 to 12 weeks or longer.

Application timing relative to other skincare steps matters. GHK-Cu serums are best applied to clean, slightly damp skin before heavier moisturizing layers, which creates a concentration gradient that drives the peptide toward the dermis rather than trapping it at the surface. If vitamin C serum is part of the routine, the two should be used in separate steps, either morning vitamin C and evening GHK-Cu, or with a waiting period between application of each to avoid the stability issues described earlier.

Frequency of use in most successful clinical trials has been twice daily, consistent with the general principle that topical actives with short skin-surface residence times benefit from frequent reapplication to maintain a sustained concentration gradient. Once-daily application is likely sufficient to produce some benefit but may underperform the twice-daily regimens studied in controlled trials.

Combination with microneedling or other minimally invasive procedures that temporarily disrupt the skin barrier represents an emerging area of clinical interest. The rationale is straightforward: disrupting the barrier eliminates the primary obstacle to GHK-Cu penetration, potentially allowing delivery to depths unreachable by passive diffusion. Several small studies have examined topical GHK-Cu application immediately after microneedling for wrinkle treatment and wound healing, with promising results, though the evidence base is not yet large enough to make definitive recommendations [5].

For hair loss applications, scalp serums containing GHK-Cu are typically applied directly to the scalp in the areas of thinning, with gentle massage to facilitate follicular uptake. The twice-daily application protocol used in the most relevant clinical study involved a leave-on formulation rather than a rinse-off product, an important distinction since rinse-off application substantially reduces contact time and likely penetration. Realistic expectations for hair density improvement are modest improvement over 4 to 6 months rather than dramatic regrowth, making GHK-Cu most appropriate as part of a multi-modal approach rather than a standalone treatment for significant hair loss.

Where the Evidence Is Strong, Where It Is Weak, and What Comes Next

A balanced assessment of GHK-Cu requires intellectual honesty about what the current evidence can and cannot support. The mechanistic picture is compelling and increasingly detailed. The in vitro and animal data are robust and consistent across independent research groups. The human clinical evidence for skin collagen, texture, and wound healing is moderate in quality, with several well-designed controlled trials supporting clinically meaningful effects. For hair loss, the mechanistic case is strong but the human randomized controlled trial evidence remains limited.

What the evidence does not yet support is any claim that topical GHK-Cu produces effects equivalent to injectable administration for systemic outcomes, or that it meaningfully extends human lifespan, or that it outperforms prescription retinoids as a first-line anti-aging intervention in the absence of comparative trial data. These are not arguments against using GHK-Cu topically; they are arguments for using it with calibrated expectations.

The gaps in the evidence base point toward where research is heading. Larger randomized controlled trials with longer follow-up periods, standardized outcome measures, and head-to-head comparisons against retinoids and other established topical actives are the priority need. Better characterization of optimal formulation parameters, particularly the effect of encapsulation technologies on bioavailability, would help translate the mechanistic insight into more consistently effective products. And for the hair loss application specifically, trials adequately powered to detect the effect sizes seen in earlier small studies would substantially advance the evidence base.

In the meantime, the existing evidence supports a clear practical conclusion: topical GHK-Cu in a well-formulated product at adequate concentration, applied consistently to skin or scalp, produces biologically meaningful effects at the tissue level and clinically detectable improvements in skin structure and appearance over a period of months. It belongs in the category of evidence-supported topical interventions, not among the many cosmetic ingredients that generate marketing excitement without scientific substance.

Conclusion: A Molecule Worth Taking Seriously

The story of GHK-Cu began with a curious observation about liver tissue in a plasma fraction from young adults, and it has evolved over five decades into one of the more scientifically substantiated chapters in the biology of skin aging. The declining trajectory of GHK-Cu plasma concentrations across the human lifespan, from the regenerative concentrations of young adulthood to the depleted levels of late middle age, suggests that this tripeptide occupies a position in the biology of aging that most cosmetic ingredients do not: it is not a molecule that happens to have useful effects, it is a molecule whose absence tracks with the loss of regenerative capacity that defines aging tissue.

Topical application concentrates its effects precisely where most people most want them: the dermis, the follicle, the healing wound. The penetration barrier is real but surmountable with appropriate formulation science. The clinical evidence for collagen remodeling and skin quality is moderate and growing. The case for hair applications is mechanistically strong and clinically promising, if not yet clinically definitive. And the comparison to injectable GHK-Cu is not a story of inferiority but of different tools for different targets.

What makes GHK-Cu genuinely interesting from a longevity perspective is not any single effect but the breadth of biology it touches: inflammation, matrix remodeling, DNA repair, mitochondrial support, and stem cell activation. These are not orthogonal effects in an otherwise healthy molecule that happens to reduce wrinkles. They are the molecular correlates of the difference between tissue that is aging well and tissue that is not. The question worth asking is not whether a tripeptide can slow skin aging. The emerging evidence suggests it can. The more important question is what it reveals about the possibility of maintaining regenerative biology in tissues that have largely forgotten how.